The emerging field of HCV drug resistance

Bibliography

• Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62
   PubMed Web of Science ®Google Scholar
• Kolykhalov AA, Agapov EV, Blight KJ, et al. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 1997;277:570-4
   PubMed Web of Science ®Google Scholar
• Yanagi M, Purcell RH, Emerson SU, Bukh J. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc Natl Acad Sci USA 1997;94:8738-43
   PubMed Web of Science ®Google Scholar
• Lohmann V, Korner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285:110-3
   PubMed Web of Science ®Google Scholar
• Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003;426:186-9
   PubMed Web of Science ®Google Scholar
• Afdhal N, Godofsky E, Dienstag J, et al. Final phase I/II trial results for NM283, a new polymerase inhibitor for hepatitis C: antiviral efficacy and tolerance in patients with HCV-1 infection, including previous interferon failures. The 55th Annual Meeting of AASLD. Hepatology 2004;40:726A. Abstract LB03
   Google Scholar
• Migliaccio G, Tomassini JE, Carroll SS, et al. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem 2003;278:49164-70
   PubMed Web of Science ®Google Scholar
• De Francesco R, Tomei L, Altamura S, et al. Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Res 2003;58:1-16
   PubMed Web of Science ®Google Scholar
• Le Pogam S, Jiang WR, Leveque V, et al. In vitro selected Con1 subgenomic replicons resistant to 2′-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology 2006;351:349-59
   PubMed Web of Science ®Google Scholar
• Mo H, Lu L, Pilot-Matias T, et al. Mutations conferring resistance to a hepatitis C virus HCV; RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrob Agents Chemother 2005;49:4305-14
   PubMed Web of Science ®Google Scholar
• Lu L, Dekhtyar T, Masse S, et al. Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro. Antiviral Res 2007;76:93-7
   PubMed Web of Science ®Google Scholar
• Tomei L, Altamura S, Bartholomew L, et al. Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. J Virol 2004;78:938-46
   PubMed Web of Science ®Google Scholar
• Nguyen TT, Gates AT, Gutshall LL, et al. Resistance profile of a hepatitis C virus RNA-dependent RNA polymerase benzothiadiazine inhibitor. Antimicrob Agents Chemother 2003;47:3525-30
   PubMed Web of Science ®Google Scholar
• Molla A, Wagner R, Lu L, et al. Characterization of pharmacokinetic/pharmacodynamic parameters for the novel HCV polymerase inhibitor A-848837. 42nd Annual Meeting of the European Association for the Study of the Liver. Barcelona, Spain, 11-15 April 2007
   Google Scholar
• Gray F, Amphlett E, Bright H, et al. GSK625433: a novel and highly potent inhibitor of the HCV NS5B polymerase. 42nd Annual Meeting of the European Association for the Study of the Liver. Barcelona, Spain, 11-15 April 2007
   Google Scholar
• Howe AY, Cheng H, Johann S, et al. Identification and characterization of HCV replicon variants with reduced susceptibility to HCV-796. 13th International Meeting on Hepatitis C Virus and Related Viruses. Cairns, Australia, 27-31 August 2006
   Google Scholar
• Bright H, Bentley K, Carroll T, et al. Selection and characterization of HCV mutants resistant to an R200-hinge site inhibitor of NS5B polymerase. 13th International Meeting on Hepatitis C Virus and Related Viruses. Cairns, Australia, 27-31 August 2006
   Google Scholar
• Wang M, Ng KK, Cherney MM, et al. Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition. J Biol Chem 2003;278:9489-95
   PubMed Web of Science ®Google Scholar
• Chan L, Pereira O, Reddy TJ, et al. Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 2. Tertiary amides. Bioorg Med Chem Lett 2004;14:797-800
   PubMed Web of Science ®Google Scholar
• Chan L, Das SK, Reddy TJ, et al. Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 1. Sulfonamides. Bioorg Med Chem Lett 2004;14:793-6
   PubMed Web of Science ®Google Scholar
• Love RA, Parge HE, Yu X, et al. Crystallographic identification of a noncompetitive inhibitor binding site on the hepatitis C virus NS5B RNA polymerase enzyme. J Virol 2003;77:7575-81
   PubMed Web of Science ®Google Scholar
• Gopalsamy A, Lim K, Ciszewski G, et al. Discovery of pyrano[3,4-b]indoles as potent and selective HCV NS5B polymerase inhibitors. J Med Chem 2004;47:6603-8
   PubMed Web of Science ®Google Scholar
• Howe AY, Bloom J, Baldick CJ, et al. Novel nonnucleoside inhibitor of hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 2004;48:4813-21
   PubMed Web of Science ®Google Scholar
• Harper S, Avolio S, Pacini B, et al. Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase. J Med Chem 2005;48:4547-57
   PubMed Web of Science ®Google Scholar
• Harper S, Pacini B, Avolio S, et al. Development and preliminary optimization of indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase. J Med Chem 2005;48:1314-7
   PubMed Web of Science ®Google Scholar
• Beaulieu PL, Bos M, Bousquet Y, et al. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery and preliminary SAR of benzimidazole derivatives. Bioorg Med Chem Lett 2004;14:119-24
   PubMed Web of Science ®Google Scholar
• Beaulieu PL, Bos M, Bousquet Y, et al. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency. Bioorg Med Chem Lett 2004;14:967-71
   PubMed Web of Science ®Google Scholar
• Beaulieu PL, Bousquet Y, Gauthier J, et al. Non-nucleoside benzimidazole-based allosteric inhibitors of the hepatitis C virus NS5B polymerase: inhibition of subgenomic hepatitis C virus RNA replicons in Huh-7 cells. J Med Chem 2004;47:6884-92
   PubMed Web of Science ®Google Scholar
• Hirashima S, Suzuki T, Ishida T, et al. Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109. J Med Chem 2006;49:4721-36
   PubMed Web of Science ®Google Scholar
• Howe AY, Cheng H, Thompson I, et al. Molecular mechanism of a thumb domain hepatitis C virus nonnucleoside RNA-dependent RNA polymerase inhibitor. Antimicrob Agents Chemother 2006;50:4103-13
   PubMed Web of Science ®Google Scholar
• Le Pogam S, Kang H, Harris SF, et al. Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus. J Virol 2006;80:6146-54
   PubMed Web of Science ®Google Scholar
• Shi S, Herlihy K, Gonzales J, et al. In vitro resistance studies of AG-021541, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. 57th Annual Meeting of AASLD. Hepatology 2006;44(S1):534A. Abstract 931
   Google Scholar
• Tomei L, Altamura S, Bartholomew L, et al. Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J Virol 2003;77:13225-31
   PubMed Web of Science ®Google Scholar
• Kukolj G, McGibbon GA, McKercher G, et al. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J Biol Chem 2005;280:39260-7
   PubMed Web of Science ®Google Scholar
• Trozzi C, Bartholomew L, Ceccacci A, et al. In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J Virol 2003;77:3669-79
   PubMed Web of Science ®Google Scholar
• Lu L, Pilot-Matias TJ, Stewart KD, et al. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob Agents Chemother 2004;48:2260-6
   PubMed Web of Science ®Google Scholar
• Seiwert SD, Hong J, Lim SR, et al. Sequence variation of NS3/4A in HCV replicons exposed to ITMN-191 concentrations encompassing those likely to be achieved following clinical dosing. 42nd Annual Meeting of the European Association for the Study of the Liver. Barcelona, Spain, 11-15 April 2007
   Google Scholar
• Lin C, Lin K, Luong YP, et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 2004;279:17508-14
   PubMed Web of Science ®Google Scholar
• Lin C, Gates CA, Rao BG, et al. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 2005;280:36784-91
   PubMed Web of Science ®Google Scholar
• Zhou Y, Muh U, Hanzelka BL, et al. Phenotypic and structural analyses of HCV NS3 protease ARG155 variants: sensitivity to telaprevir VX-950; and interferon alpha. J Biol Chem 2007;282:22619-28
   PubMed Web of Science ®Google Scholar
• Tong X, Chase R, Skelton A, et al. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006;70:28-38
   PubMed Web of Science ®Google Scholar
• Yi M, Tong X, Skelton A, et al. Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations. J Biol Chem 2006;281:8205-15
   PubMed Web of Science ®Google Scholar
• Li K, Foy E, Ferreon JC, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA 2005;102:2992-7
   PubMed Web of Science ®Google Scholar
• Gale M Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005;436:939-45
   PubMed Web of Science ®Google Scholar
• Foy E, Li K, Sumpter R Jr, et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci USA 2005;102:2986-91
   PubMed Web of Science ®Google Scholar
• Ferreon JC, Ferreon AC, Li K, Lemon SM. Molecular determinants of TRIF proteolysis mediated by the hepatitis C virus NS3/4A protease. J Biol Chem 2005;280:20483-92
   PubMed Web of Science ®Google Scholar
• Kalkeri G, Rao G, Brennan D, Kwong A. VX-950 ameliorates HCV protease mediated immune evasion in cultured hepatocytes. 12th International Conference on HCV and Related Viruses. Montreal, Canada, 2-6 October 2005
   Google Scholar
• Howe AY, Ralston R, Chase R, et al. Favorable cross-resistance profile of two novel hepatitis C virus inhibitors, SCH-503034 and HCV-796, and enhanced anti-replicon activity mediated by the combined use of both compounds. 42nd Annual Meeting of the European Association for the Study of the Liver. Barcelona, Spain, 11-15 April 2007
   Google Scholar
• McCown M, Rajyaguru S, Symons J, et al. In vitro resistance selection to the HCV nucleoside polymerase inhibitor R1479 and to the protease inhibitor VX-950. 42nd Annual Meeting of the European Association for the Study of the Liver. Barcelona, Spain, 11-15 April 2007
   Google Scholar
• Ralston R, Bichko V, Chase R, et al. Combination of two hepatitis C virus inhibitors, SCH 503034 and NM107, provides enhanced anti-replicon activity and suppresses emergence of resistant replicons. 42nd Annual Meeting of the European Association for the Study of the Liver. Barcelona, Spain, 11-15 April 2007
   Google Scholar
• Koev G, Dekhtyar T, Han L, et al. Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro. Antiviral Res 2007;73:78-83
   PubMed Web of Science ®Google Scholar
• Koev G, Dekhtyar T, Han L, et al. In vitro antiviral effects of combinations of Abbott HCV polymerase inhibitors with IFN or NS3/4A protease inhibitors. 57th Annual Meeting of AASLD. Hepatology 2006;44(S1):346A. Abstract 417
   Google Scholar
• Najarro P, Powell K, Budworth J, et al. A-831, a novel HCV inhibitor targeting NS5A. First International Workshop on Hepatitis C Resistance and New Compounds. Boston, MA, 25-26 October 2006
   Google Scholar
• Conte IE, Guiliano C, Migliaccio G, Stansfield I. Modulators of HCV replication. WO2006038039 A1 2006
   Google Scholar
• Romine JL, Martin SW, Snyder LB, et al. Iminothiazolidinones as inhibitors of HCV replication. WO2004014852 A2 2004
   Google Scholar
• Domingo E, Menendez-Arias L, Holland JJ. RNA virus fitness. Rev Med Virol 1997;7:87-96
   PubMed Web of Science ®Google Scholar
• Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000;290:1972-4
   PubMed Web of Science ®Google Scholar
• Krieger N, Lohmann V, Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J Virol 2001;75:4614-24
   PubMed Web of Science ®Google Scholar
• Dutartre H, Bussetta C, Boretto J, Canard B. General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2′-modified nucleotide analogues. Antimicrob Agents Chemother 2006;50:4161-9
   PubMed Web of Science ®Google Scholar
• Olsen DB, Carroll SS, Handt L, et al. HCV antiviral activity and resistance analysis in chronically infected chimpanzees treated with NS3/4A protease and NS5B polymerase inhibitors. 42nd Annual Meeting of the European Association for the Study of the Liver. Barcelona, Spain, 11-15 April 2007
   Google Scholar
• Lawitz E, Nguyen T, Younes Z, et al. Valopicitabine NM283; plus PEG-interferon in treatment-naive hepatitis C patients with HCV genotype 1 infection: HCV RNA clearance during 24 weeks of treatment. 57th Annual Meeting of AASLD. Hepatology 2006;44(S1):223A. Abstract 93
   Google Scholar
• Roberts S, Cooksley G, Dore G, et al. Results of a phase 1b, multiple dose study of R1626, a novel nucleoside analog targeting HCV polymerase in chronic HCV genotype 1 patients. 57th Annual Meeting of AASLD. Hepatology 2006;44(S1):692A. Abstract LB2
   Google Scholar
• Chen CM, He Y, Lu L, et al. Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model. Antimicrob Agents Chemother 2007;51:4290-6
   PubMed Web of Science ®Google Scholar
• Chen CM, He Y, Lu L, et al. The antiviral efficacy of an HCV polymerase inhibitor in the chimpanzee model: genotypic and phenotypic analyses. 57th Annual Meeting of AASLD. Hepatology 2006;44(S1):342A. Abstract 406
   Google Scholar
• Villano S, Howe A, Raible D, et al. Analysis of HCV NS5B genetic variants following monotherapy with HCV-796, a non-nucleoside polymerase inhibitor, in treatment-naive HCV-infected patients. 57th Annual Meeting of AASLD. Hepatology 2006;44(S1):607A. Abstract 1127
   Web of Science ®Google Scholar
• Le Pogam S, Kosaka A, Hu S, et al. R1479, a novel hepatitis C polymerase inhibitor: lack of pre-existing resistance mutation supports the observed in vivo high barrier to resistance. 42nd Annual Meeting of the European Association for the Study of the Liver. Barcelona, Spain, 11-15 April 2007
   Google Scholar
• Middleton T, He Y, Pilot-Matias T, et al. A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populations. J Virol Methods 2007;145:137-45
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007;132:1767-77
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007;132:1270-8
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Sarrazin C, Rouzier R, et al. Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype 1 HCV-1; patients refractory to pegylated interferferon PEG-IFN-alpha;. 56th Annual Meeting of AASLD. Hepatology 2005;42(S1):233A. Abstract 94
   Google Scholar
• Zeuzem S, Sarrazin C, Wagner F, et al. Combination therapy with the HCV protease inhibitor, SCH 503034, plus Peg-Intron in hepatitis C genotype-1Peg-Intron non-responders: phase 1b results. 56th Annual Meeting of AASLD. Hepatology 2005;42(S1):276A. Abstract 201
   Web of Science ®Google Scholar
• Kieffer TL, Sarrazin C, Miller J, et al. Combination of Telaprevir VX-950; and PEG-IFN-Alpha suppresses both wild type virus and resistance variants in HCV genotype 1-infected patients in a 14-day phase 1b study. 57th Annual Meeting of AASLD. Hepatology 2006;44(S1):222A. Abstract 92
   Google Scholar
• Forestier N, Weegink C, Purdy S, et al. Current status of subjects receiving Peg-Interferon-Alpha-2a Peg-IFN-2a; and Ribavirin RBV; after a 14-day study of the hepatitis C protease inhibitor Telaprevir VX-950;, with Peg-IFN-2a. 57th Annual Meeting of AASLD. Hepatology 2006;44(S1):614A. Abstract 1142
   Google Scholar
• Forestier N, Susser S, Welker MW, et al. Telaprevir resistance mutations in patients with hepatitis C who relapsed after sequential therapy with telaprevir, peginterferon alfa 2a and ribavirin. 58th Annual Meeting of AASLD. Hepatology 2007;46(S1):255A. Abstract 50
   Google Scholar
• Rodriguez-Torres M, Lawitz EJ, McHutchison JG. Final results of patients treated with peg-interferon-alfa-2a Peg-IFN; and ribavirin RBV; follow-on therapy after 28-day treatment with the hepatitis C protease inhibitor Telaprevir VX-950;, Peg-IFN and RBV. 58th Annual Meeting of AASLD. Hepatology 2007;46(S1):314A-315A. Abstract 175
   Google Scholar
• McHutchison JG, Everson GT, Gordon S, et al. Results of an interim analysis of a phase 2 study of telaprevir VX-950; with peginterferon alfa-2a and ribavirin in previously untreated subjects with hepatitis C. 42nd Annual Meeting of the European Association for the Study of the Liver. Barcelona, Spain, 11-15 April 2007
   Google Scholar
• Jacobson IM, Everson GT, Gordon SC, et al. Interim analysis results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naïve subjects with hepatitis C. 58th Annual Meeting of AASLD. Hepatology 2007;46(S1):315A-6A. Abstract 177
   PubMed Web of Science ®Google Scholar
• Kieffer T, Zhou Y, Zhang E, et al. Evaluation of viral variants during a phase 2 study PROVE2; of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naïve HCV genotype 1-infected patients. 58th Annual Meeting of AASLD. Hepatology 2007;46(S1):862A-863A. Abstract LB8
   Google Scholar
• Zeuzem S, CH, Ferenci P, Dusheiko GM, et al. PROVE2: phase II study of VX950 TELAPREVIR; in combination with peginterferon alfa2a with or without ribavirin in subjects with chronic hepatitis C, first interim analysis. 58th Annual Meeting of AASLD. Hepatology 2007;46(S1):Abstract 80
   Google Scholar
• Perelson A. HCV viral kinetics. First International Workshop on Hepatitis C Resistance and New Compounds. Boston, MA, USA, 25-26 October 2006
   Google Scholar
• Garg V, Khunvichai A, Chu H, et al. Predicting HCV treatment duration with an HCV protease inhibitor co-administered with Peg-IFN/RBV by modeling both wild type virus and low level resistant variant dynamics. Digestive Diseases Week 2007. Washington, DC, USA, May 19-24, 2007
   Google Scholar
• Blackard JT, Kemmer N, Sherman KE. Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. Hepatology 2006;44:15-22
   PubMed Web of Science ®Google Scholar
• Kempf DJ, Klein C, Chen HJ, et al. Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir. Antivir Chem Chemother 2007;18:163-7
   PubMedGoogle Scholar
• Ludmerer SW, Graham DJ, Boots E, et al. Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob Agents Chemother 2005;49:2059-69
   PubMed Web of Science ®Google Scholar